AGLHealthcare · Medical Care FacilitiesThe 15 Wall Street analysts covering Agilon Health, Inc. hold a median 12-month price target of $115 — +19.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Agilon Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (6): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on AGL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +19.5% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Sept 2026 | Bernstein | Upgrade | Outperform | $86 → $125 |
| 24 Aug 2026 | JP Morgan | Maintains | Underweight | — |
| 24 Aug 2026 | JP Morgan | Maintains | Underweight | $31 → $85 |
| 11 Aug 2026 | Citigroup | Upgrade | Neutral | — |
| 11 Aug 2026 | Citigroup | Upgrade | Neutral | $105 → $115 |
| 11 Aug 2026 | Wells Fargo | Maintains | Overweight | $141 → $146 |
| 11 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 6 Aug 2026 | Barclays | Maintains | Equal-Weight | $81 → $111 |
| 6 Aug 2026 | Barclays | Maintains | Equal-Weight | — |
| 6 Aug 2026 | Benchmark | Maintains | Buy | — |
| 6 Aug 2026 | Benchmark | Maintains | Buy | $95 → $140 |
| 6 Aug 2026 | Evercore ISI Group | Maintains | In-Line | $120 → $125 |
| 6 Aug 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 6 Aug 2026 | Truist Securities | Maintains | Hold | — |
| 6 Aug 2026 | Truist Securities | Maintains | Hold | $67 → $112 |
| 23 July 2026 | Citigroup | Downgrade | Sell | — |
| 23 July 2026 | Citigroup | Downgrade | Sell | $80 → $105 |
| 13 July 2026 | Wells Fargo | Maintains | Overweight | $72 → $141 |
| 13 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 26 May 2026 | Barclays | Upgrade | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AGL appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Agilon Health, Inc. returned +431.7% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 90% of US stocks
Cheaper than 14% of US stocks
Cheaper than 81% of US stocks
Higher than 46% of US stocks
Higher than 45% of US stocks
Higher than 7% of US stocks
Higher than 47% of US stocks
Higher than 25% of US stocks
Higher than 16% of US stocks
Higher than 27% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Agilon Health, Inc. has a market value of $1.6B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $5.9B. The latest quarter grew 7.2% year on year.
Net income over the same four quarters: −$232.2M, a −3.9% net margin.
Diluted earnings per share, trailing twelve months: $−14.27.
Free cash flow in the twelve months to 30 June 2026: −$106.0M.
Trailing P/E: −4.0×; forward P/E: 40.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Agilon Health, Inc. employs 856 people — $6.9M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Agilon Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Agilon Health raised its full-year 2026 outlook after third-quarter results exceeded its guidance. The company attributed performance to higher risk-adjustment revenue, clinical program performance and favorable medical cost development in the first half of the year.
Why it matters — The results and raised outlook provide AGL watchers an update on the company’s operating performance and expectations for the full year.
Zacks Investment Research says Agilon’s Q3 headline results for the quarter ended September 2026 can be assessed alongside key metrics, Wall Street estimates, and year-ago actuals. The excerpt does not provide the metrics or comparison outcomes.
Why it matters — These comparisons can help AGL watchers evaluate quarterly performance, though the excerpt gives no specific results.
Agilon Health reported quarterly earnings of $1.97 per share, surpassing the Zacks Consensus Estimate of a $2.01 per-share loss. The result compares with a loss of $6.75 per share a year earlier.
Why it matters — AGL watchers may note the earnings beat and the improvement from the prior-year quarterly loss.
Seeking Alpha published the transcript of agilon health, Inc. (AGL)’s Q3 2026 earnings call.
Why it matters — The transcript provides AGL watchers with the company’s commentary from its Q3 2026 earnings call.
agilon health announced results for the third quarter ended September 30, 2026. CEO Tim O’Rourke said the results exceeded expectations and cited disciplined execution and operational progress.
Why it matters — AGL watchers may note management’s characterization of the quarter’s results and progress.
The 15 Wall Street analysts covering Agilon Health, Inc. have a median 12-month price target of $115, with estimates ranging from $85 to $146. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Agilon Health, Inc., 5 rate it a Buy, 9 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Agilon Health, Inc. 62 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Agilon Health, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +19.5% from the last close, and Ticker Nerd's factor model ranks Agilon Health, Inc. 62 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Agilon Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $146 over the next 12 months.
Agilon Health, Inc. returned +431.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
agilon health, Inc. is a healthcare services company focused on supporting primary care physicians in managing senior patients through value-based care arrangements.
The most recent item we track (MarketBeat, 5 Nov 2026): "Agilon Health Q3 Earnings Call Highlights". Agilon Health raised its full-year 2026 outlook after third-quarter results exceeded its guidance. The company attributed performance to higher risk-adjustment revenue, clinical program performance and favorable medical cost development in the first half of the year.
agilon health, Inc. is a healthcare services company focused on supporting primary care physicians in managing senior patients through value-based care arrangements. The company provides a platform that helps physician groups coordinate care, manage total patient health needs, and operate under capitated reimbursement models designed around Medicare beneficiaries. Its services include care coordination, payer contracting support, population health analytics, quality management, and operational infrastructure for community-based physician practices. agilon health works primarily with independent primary care groups across the United States, helping them deliver integrated care in local markets while shifting administrative and clinical support tasks to its platform. The company plays a role in the broader healthcare market by enabling physician-led models that emphasize coordinated treatment, preventive care, and management of chronic conditions for older adults.
CEO Mr. Timothy Patrick O'Rourke · 856 employees · United States · https://www.agilonhealth.com
